 |
> 2001 Publications
1.
The D’Amico Article Reviewed: The CPDR/CaPSURE
Recurrence Equation.
Moul JW.
Oncology, 15:1060-1062, 2001. |
2.
Use of Serum Creatinine to Predict Pathologic Stage and Recurrence
Among Radical Prostatectomy Patients.
Merseburger AS, Connelly RR, Sun L, Richter E, Moul JW:
Urology, 58:729-734, 2001. |
3.
The Development of Erectile Dysfunction in Men Treated
for Prostate Cancer.
Siegel T, Moul JW, Spevak M, Alvord WG, and Costabile RA:
Journal of Urology, Vol. 165,430-435, 2001. |
4. PSA Enhanced Testing and Risk Stratification for
Chemoprevention Trials.
Moul JW:
Urology, 57 (Suppl 4A): 174-177, 2001. |
5. A comparison of radical retropubic with perineal
prostatectomy for localized prostate cancer within the Uniformed
Services Urology Research Group.
Lance RS, Freidrichs PA, Kane C, Powell CR, Pulos E, Moul JW,
McLeod DG, Cornum RL, and Thrasher JB:
BJU International. Vol. 87:61-65, 2001. |
6.
Quantitative Expression Profile of Androgen-Regulated
Genes in Prostate Cancer Cells and Identification of Prostate-Specific
Genes.
Xu LL, Su YP, LaBiche R, Segawa T, Shanmugam N, McLeod, Moul
JW and Srivastava S:
Int. J. Cancer, Vol. 92:322-328, 2001. |
7.
Clinical Staging of Prostate Cancer: Reproducibility
and Clarification of Issues.
Campbell T, Blasko J, Crawford ED, Forman J, Hanks G, Kuban
D, Montie J, Moul JW, Pollack A, Raghavan D, Ray P, Roach III
M, Steinberg G, Stone N, Thompson I, Vogelzang N, and Vijayakumar
S:
Int. J. Cancer. (Radiat. Oncol. Invest), 96:198-209, 2001. |
8.
Age-Specific Reference Ranges for Prostate Specific
Antigen in Young Men: Retrospective Study from the National
Defense University.
Hartzell JD, Kao TC, Holland JC, Holt SR, and Moul JW:
The Prostate Journal, 3:36-41, 2001. |
9.
The Effect of Ethnicity on Biochemical Disease-Free
Outcome in Patients with Prostate Cancer Treated with Definitive
Radiation Therapy in an Equal-Access Health Care System: A Radiation
Oncology Report of the Department of Defense Center for Prostate
Disease Research.
Johnstone P, Kane C, Sun L, Wu H, Moul JW, et al:
Radiology, 2001. |
10.
Predicting risk of prostate specific antigen recurrence
after radical prostatectomy with the Center for Prostate Disease
Research and Cancer of the Prostate Strategic Urologic Research
Endeavor databases.
Moul JW, Connelly RR, Lubeck DP, Bauer JJ, Sun L, Flanders SC,
Grossfeld GD, Carroll PR:
J Urol, 166:1322-1327, 2001. |
11.
Prostate specific antigen kinetics at tumor recurrence
after radical prostatectomy do not suggest a worse disease prognosis
in black men.
Bissonette EA, Fulmer BR, Petroni GR, Moul
JW, Theodorescu D:
J Urol, 166:1328-31, 2001. |
12.
A novel human cancer culture model for the study of prostate
cancer.
Yasunaga Y, Nakamura K, Ko D, Srivastava S, Moul JW,
Sesterhenn IA, McLeod DG, Rhim J:
Oncogene, 20:8036-8041, 2001. |
13.
Changing face and different countenances of prostate cancer:
Racial and geographic differences in prostate-specific antigen
(PSA), stage, and grade trends in the PSA era.
Jani AB, Vaida F, Hanks, G, Asbell S, Sartor O, Moul JW, Raoch
M 3rd, Brachman D, Kalokhe U, Muller-Runkel R, Ray P, Ignacio
L, Awan A, Weichselbaum RR, and Vijayakumar S:
Int J Cancer, 96:363-371, 2001. |
14. Improvements in Pathological Staging for African-American
Men Undergoing Radical Retropubic Prostatectomy During the Prostate-Specific
Antigen Era – Implications for Screening a High-Risk Group
for Prostate Carcinoma.
Paquette EL, Connelly RR, Sesterhenn IA, Zhang W, Sun L, Paquette
LR, Greenspan R, Mcleod DG, Moul, JW:
Cancer, 92:2673-2679, 2001. |
15. Relationship Between Obesity and Race in Predicting
Adverse Pathologic Variables in Patients Undergoing Radical Prostatectomy.
Amling CL, Kane CJ, Riffenburgh RH, Ward JF, Roberts JL, Lance
RS, Freidrichs PA, Moul JW:
Urolog, 58:723-728,2001. |
16.
Managing advanced prostate cancer with Viadur (leuprolide
acetate implant).
Moul JW, Civitelli K:
Urol Nurs, 21:385-8, 393-4; quiz 395-6, 2001. |
17.
Prostate biopsy protocols: 3D visualization-based evaluation
and clinical correlation.
Zeng J, Bauer J, Zhang W, Sesterhenn I, Connelly R, Lynch J, Moul
J, Mun SK:
Comput Aided Surg, 6:14-21, 2001. |
18.
The Role of Imaging Studies and Molecular Markers for Selecting
Candidates for Radical Prostatectomy.
Moul JW, Kane CJ, and Malkowicz SB:
Urol Clinics of North America, Volume 28, Number 3, August
2001. |
19.
A Novel Human Cell Culture Model for the Study of Familial
Prostate Cancer.
Yasunaga Y, Nakamura K, Ewing CM, Isaacs WB, Hukku B and Rhim
JS:
Cancer Research, 61:5969-5973, August 2001. |
20.
Introduction to department of defense center for prostate
disease research (CPDR) multicenter national prostate cancer database
with 242,227 records on 11,637 men, and analysis of changes in
the PSA-era.
Sun L, Gancarczyk K, McLeod DG, Kane C, Kusuda L, Lance R, Herring
J, Foley J, Baldwin D, Bishoff JT, Soderdahl D, Wu H, Xu L, Moul
JW.
Urol Oncol 2001. |
 Back
to Top |
|
